Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$1.83 -4.2%	$3.08	$1.33 ▼ $27.93	$1.56M	0.44	111,869 shs	90,580 shs
CHEK Check-Cap	$2.26 +3.7%	$2.24	$1.27 ▼ $4.63	$13.22M	0.28	220,543 shs	42,717 shs
TPST Tempest Therapeutics	$3.17 -3.1%	$3.80	$0.17 ▼ $9.77	$70.34M	-1.76	981,328 shs	315,091 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-4.19%	-21.79%	-41.53%	-52.44%	-92.11%
CHEK Check-Cap	+3.67%	-5.83%	+17.71%	+3.67%	+71.21%
TPST Tempest Therapeutics	-3.06%	-17.66%	-15.24%	-19.54%	+34.89%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	1.3347 of 5 stars	3.5	2.0	0.0	0.0	3.7	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A
CHEK Check-Cap	2.00	Hold	N/A	N/A
TPST Tempest Therapeutics	3.00	Buy	$22.25	601.89% Upside

Current Analyst Ratings

Latest CHEK, TPST, and ATNF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2024	TPST Tempest Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/20/2024	TPST Tempest Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00
3/14/2024	TPST Tempest Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$13.00
2/8/2024	TPST Tempest Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	($0.24) per share	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	$8.57 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	$1.39 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$19.93M	N/A	0.00	∞	N/A	N/A	-320.26%	-112.07%	5/20/2024 (Estimated)
CHEK Check-Cap	-$19.11M	-$3.02	N/A	N/A	N/A	N/A	-47.85%	-43.50%	5/9/2024 (Estimated)
TPST Tempest Therapeutics	-$29.49M	-$1.91	N/A	N/A	N/A	N/A	-283.87%	-82.11%	5/8/2024 (Estimated)

Latest CHEK, TPST, and ATNF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/19/2024	Q4 2023	TPST Tempest Therapeutics	-$0.38	-$0.34	+$0.04	-$0.34	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	0.72	0.72
CHEK Check-Cap	N/A	17.60	17.60
TPST Tempest Therapeutics	0.23	4.29	4.29

Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
CHEK Check-Cap	1.07%
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	4.10%
CHEK Check-Cap	0.48%
TPST Tempest Therapeutics	5.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	5	850,000	818,000	No Data
CHEK Check-Cap	85	5.85 million	5.82 million	Not Optionable
TPST Tempest Therapeutics	17	22.19 million	20.91 million	Optionable

CHEK, TPST, and ATNF Headlines

Source	Headline
	Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 26.5% in March americanbankingnews.com - April 15 at 5:16 AM
	Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 6.8% americanbankingnews.com - April 14 at 6:00 AM
	Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update marketbeat.com - April 13 at 1:10 PM
	Tempest Therapeutics (NASDAQ:TPST) Trading Down 6.8% marketbeat.com - April 13 at 12:40 AM
	Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments markets.businessinsider.com - April 9 at 5:53 PM
	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting finance.yahoo.com - April 9 at 12:51 PM
	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting globenewswire.com - April 9 at 8:00 AM
	Tempest Therapeutics moves TPST-1120 into phase 3 trial uk.investing.com - April 6 at 3:43 PM
	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications finance.yahoo.com - April 4 at 8:14 AM
	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications globenewswire.com - April 4 at 8:00 AM
	Q3 2024 Earnings Estimate for Tempest Therapeutics, Inc. (NASDAQ:TPST) Issued By HC Wainwright marketbeat.com - March 22 at 8:18 AM
	Research Analysts Issue Forecasts for Tempest Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TPST) marketbeat.com - March 21 at 8:01 AM
	Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST) markets.businessinsider.com - March 21 at 6:39 AM
	Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update finanznachrichten.de - March 20 at 3:37 PM
	William Blair Reiterates "Outperform" Rating for Tempest Therapeutics (NASDAQ:TPST) marketbeat.com - March 20 at 11:19 AM
	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 investorplace.com - March 19 at 11:07 PM
	Tempest Reports Year End 2023 Financial Results and Provides Business Update finance.yahoo.com - March 19 at 8:50 PM
	Tempest Reports Year End 2023 Financial Results and Provides Business Update globenewswire.com - March 19 at 4:25 PM
	Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST) businesswire.com - March 14 at 3:56 PM
	Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects markets.businessinsider.com - March 12 at 8:31 PM
	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types finance.yahoo.com - March 12 at 10:29 AM
	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting globenewswire.com - March 5 at 4:30 PM
	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference finance.yahoo.com - February 26 at 2:06 PM
	Tempest Therapeutics, Inc. (TPST) finance.yahoo.com - January 30 at 12:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

180 Life Sciences

NASDAQ:ATNF

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Check-Cap

NASDAQ:CHEK

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Tempest Therapeutics

NASDAQ:TPST

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial